Table 1.

Patient characteristics of 9 patients with known mutations in BCR-ABL following the development of imatinib resistance.

Patient	Age/Sex	Months on Imatinib until resistance	HLA-A and -B alleles	BCR-ABL Mutations
1	64/M	32	A3, A11, B7, B52	L150M, E255K, T315I,
2	44/M	6	A2, A3, B7, B49	E255K
3	59/M	2	A2, A3, B7, B44	E255K
4	53/M	6	A2, A33, B37, B14	E255K, T315I
5	70/M	1	A1, A2, B8, B38	M244V, E281K, T315A
6	61/M	14	A2, A2, B40, B51	G250E
7	48/F	2	A1, A30, B18, B57	V379I
8	58/F	7	A1, A31, B7, B57	T315I
9	64/F	33	A1, A24, B8, B57	E281K, G254R